Photocure $PHO.OL stock trade above resistance, close at 5yr hgh
Recent news by 
PHO:
Randomized phase 3 study in Denmark demonstrates significant advantage in Bladder Cancer for Hexvix/Cysview blue light cystoscopy over standard white light variant:
https://photocure.com/news/photocurefirst-trial-demonstrating-reduced-recurrence-after-flexible-blue-light-cystoscopy-with-hexvix-in-surveillance/
At Q3 2019 Photocure reported continued record growth in the US as well as upfront payments from Chinese partner Asieris:
https://photocure.com/news/photocure-asa-results-for-the-third-quarter-of-2019/
Further improvements for US reimbursements for Cysview from january 2020:
https://photocure.com/news/photocure-cysview-reimbursement-further-improved-from-january-2020/
Technical analysis:
Technical indicators sliding into high momentum and near overbought values at this price level, so any entry should be done with clear considerations of short term risks.
PHO:Randomized phase 3 study in Denmark demonstrates significant advantage in Bladder Cancer for Hexvix/Cysview blue light cystoscopy over standard white light variant:
https://photocure.com/news/photocurefirst-trial-demonstrating-reduced-recurrence-after-flexible-blue-light-cystoscopy-with-hexvix-in-surveillance/
At Q3 2019 Photocure reported continued record growth in the US as well as upfront payments from Chinese partner Asieris:
https://photocure.com/news/photocure-asa-results-for-the-third-quarter-of-2019/
Further improvements for US reimbursements for Cysview from january 2020:
https://photocure.com/news/photocure-cysview-reimbursement-further-improved-from-january-2020/
Technical analysis:
Technical indicators sliding into high momentum and near overbought values at this price level, so any entry should be done with clear considerations of short term risks.
Bài đăng liên quan
Thông báo miễn trừ trách nhiệm
Thông tin và ấn phẩm không có nghĩa là và không cấu thành, tài chính, đầu tư, kinh doanh, hoặc các loại lời khuyên hoặc khuyến nghị khác được cung cấp hoặc xác nhận bởi TradingView. Đọc thêm trong Điều khoản sử dụng.